Tekla Capital Management LLC historic quarter change: Foreign Stocks, Added
In share positions in stocks (depositary receipts and foreign shares traded over the counter), over 13 quarters from 2013-06-30 to 2016-09-30, Tekla Capital Management LLC opened 12 positions, added to 16, reduced 7 and sold out of 5.
- Q3 2016: Stock NVS; Country of operation —; Class Sponsored ADR; Shares before 170,100.
- Q3 2016: Stock ADAPY; Country of operation United Kingdom; Class Sponsored ADR; Shares before 296,934.
- Q2 2016: Stock LKFT; Country of operation —; Class Sponsored ADR; Shares before 20,000.
- Q2 2016: Stock NVS; Country of operation —; Class Sponsored ADR; Shares before 92,700.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1300336), 13 quarters: Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-09); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-09); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-13); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-12); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-06); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-01-30); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-05); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-13); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-01-28); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-10-30). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2004-06-30.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q3 2016 | NVS
Novartis AG | | Sponsored ADR | 170,100 | 248,800 | +78,700 | $14,035,000 | $19,645,000 | +$5,610,000 | 2016-11-14 |
|---|
| Q3 2016 | ADAPY
Adaptimmune Theraputics plc | United Kingdom | Sponsored ADR | 296,934 | 566,368 | +269,434 | $2,420,000 | $3,993,000 | +$1,573,000 | 2016-11-14 |
|---|
| Q2 2016 | LKFT
Galapagos NV | | Sponsored ADR | 20,000 | 147,738 | +127,738 | $836,000 | $8,195,000 | +$7,359,000 | 2016-08-12 |
|---|
| Q2 2016 | NVS
Novartis AG | | Sponsored ADR | 92,700 | 170,100 | +77,400 | $6,715,000 | $14,035,000 | +$7,320,000 | 2016-08-12 |
|---|
| Q1 2016 | CLLS
Cellectis S.A. | | Sponsored ADS | 207,250 | 310,250 | +103,000 | $6,431,000 | $8,532,000 | +$2,101,000 | 2016-05-09 |
|---|
| Q1 2016 | GRFS
Grifols SA | | Sponsored ADR | 83,000 | 166,000 | +83,000 | $2,689,000 | $2,568,000 | -$121,000 | 2016-05-09 |
|---|
| Q4 2015 | CLLS
Cellectis S.A. | | Sponsored ADS | 158,382 | 207,250 | +48,868 | $4,175,000 | $6,431,000 | +$2,256,000 | 2016-02-09 |
|---|
| Q4 2015 | ADAPY
Adaptimmune Therapeutics plc | United Kingdom | Sponsored ADR | 281,934 | 296,934 | +15,000 | $3,375,000 | $3,581,000 | +$206,000 | 2016-02-09 |
|---|
| Q3 2015 | ADAPY
Adaptimmune Therapeutics plc | United Kingdom | Sponsored ADR | 27,500 | 281,934 | +254,434 | $504,000 | $3,375,000 | +$2,871,000 | 2015-11-13 |
|---|
| Q3 2015 | CLLS
Cellectis S.A. | | Sponsored ADS | 40,000 | 158,382 | +118,382 | $1,443,000 | $4,175,000 | +$2,732,000 | 2015-11-13 |
|---|
| Q2 2015 | TEVA
Teva Pharmaceutical Industries Ltd. | | ADR | 997,594 | 1,387,594 | +390,000 | $62,150,000 | $82,007,000 | +$19,857,000 | 2015-08-12 |
|---|
| Q1 2015 | TEVA
Teva Pharmaceutical Industries Ltd. | | ADR | 423,594 | 997,594 | +574,000 | $24,361,000 | $62,150,000 | +$37,789,000 | 2015-05-06 |
|---|
| Q3 2014 | TEVA
Teva Pharmaceutical Industries Ltd. | | ADR | 311,476 | 652,194 | +340,718 | $16,328,000 | $35,055,000 | +$18,727,000 | 2014-11-14 |
|---|
| Q3 2014 | SGMOQ
Sangamo BioSciences, Inc. | United States | Common | 120,400 | 750,100 | +629,700 | $1,839,000 | $8,090,000 | +$6,251,000 | 2014-11-14 |
|---|
| Q2 2014 | SGMOQ
Sangamo BioSciences, Inc. | United States | Common | 47,400 | 120,400 | +73,000 | $857,000 | $1,839,000 | +$982,000 | 2014-08-05 |
|---|
| Q3 2013 | TEVA
Teva Pharmaceutical Industries Ltd. | | ADR | 311,476 | 354,476 | +43,000 | $12,210,000 | $13,392,000 | +$1,182,000 | 2013-10-30 |
|---|
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|
| Not available yet |